#Canada #Hamilton #radiopharmaceuticals #AtomVie

AtomVie Global Radiopharma Expands with New Manufacturing Facility in Hamilton

In a remarkable leap forward for the radiopharmaceutical industry, AtomVie Global Radiopharma has officially opened its new state-of-the-art manufacturing facility located at 10 Aeropark Boulevard in Hamilton, Ontario. This facility is not just any addition; it represents a significant investment exceeding $160 million and is poised to be the largest single-site Contract Development and Manufacturing Organization (CDMO) facility dedicated to radiopharmaceuticals in North America.

Facility Highlights

Spanning an impressive 72,300 square feet, the facility introduces low-to-high throughput production capabilities, elevating AtomVie’s manufacturing capacity by more than tenfold. This purpose-built site is designed to facilitate everything from early-stage development to full-scale commercial manufacturing of radiopharmaceuticals, thus providing customizable spaces to adapt to client needs and market demands.

CEO Bruno Paquin remarked, "This Grand Opening represents the next chapter of AtomVie's journey and a proud milestone for Canadian innovation in nuclear medicine. Our new purpose-built facility amplifies a proven track record of reliable global delivery and deep scientific expertise."

The transition from clinical success to transformative patient therapies is at the core of AtomVie’s mission. With advanced capabilities, the new facility is set to enhance the efficiency of bringing life-changing therapies to patients across the globe.

A Legacy of Excellence

AtomVie is a spinout from the Centre for Probe Development and Commercialization (CPDC) at McMaster University, established to drive Canada’s leadership in the field of radiopharmaceuticals. The company aims to reach a workforce of over 200 skilled professionals by the end of 2026, continually building on its track record of success and innovation. In its short history, AtomVie has supported more than 70 clinical development and technology transfer programs, produced over 1,000 cGMP batches, and provided more than 4,400 cGMP doses to patients across 28 countries globally, boasting a remarkable delivery success rate of over 99%.

Commitment to Quality and Growth

Kevin McNeill, Chairman of AtomVie’s Board of Directors, highlighted the dedication and discipline of the entire AtomVie team, stating, "This facility underscores AtomVie’s ongoing status as a leader in the radiopharmaceutical CDMO sector, built at commercial scale to meet the reliability demands of our partners."

The Grand Opening event attracted various stakeholders, including government representatives, clients, and members of the radiopharmaceutical community, offering tours that showcased AtomVie’s cutting-edge technology and commitment to the next generation of precision cancer therapies.

Conclusion

With the launch of this advanced manufacturing facility, AtomVie Global Radiopharma is not just enhancing its production capabilities; it is also reinforcing its commitment to improving patient outcomes through innovative therapies. The facility serves as a critical step in the evolution of the company, set to meet the growing demands of the radiopharmaceutical market and push the boundaries of what is achievable in nuclear medicine. For those interested in learning more about AtomVie and its pioneering work in radiopharmaceuticals, additional information can be found on their official website: AtomVie.com.